You are here

  • Home
  • Archive
  • Volume 74, Issue 8
  • Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study

Article info

Article menu

Download PDFPDF

Electronic pages
Correspondence
Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study
Free

Authors

  1. Correspondence to Dr Raimon Sanmarti, Rheumatology Department, Hopsital Clinic de Barcelona, Villarroel 170, Barcelona 08036, Spain; sanmarti{at}clinic.cat
View Full Text

Citation

Sanmarti R, Inciarte-Mundo J, Estrada-Alarcon P, et al
Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study
Annals of the Rheumatic Diseases 2015;74:e42.

Publication history

  • Received March 2, 2015
  • Accepted March 3, 2015
  • First published March 24, 2015.
Online issue publication 
June 30, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions